Phase I study of temsirolimus (CCI-779) and sorafenib in recurrent glioblastoma: North central cancer treatment group (NCCTG) N0572

被引：0

作者：

Schiff, David ^{[1
]}

Sarkaria, Jann ^{[2
]}

Decker, Paul ^{[2
]}

Buckner, Jan ^{[2
]}

Galanis, Evanthia ^{[2
]}

Dancey, Janet ^{[3
]}

Giannini, Caterina ^{[2
]}

Brown, Paul ^{[2
]}

Wiesenfeld, Martin ^{[4
]}

Jaeckle, Kurt ^{[5
]}

机构：

[1] Univ Virginia, Hlth Sci Ctr, Charlottesville, VA USA

[2] Mayo Clin, Rochester, MN USA

[3] Natl Canc Inst, Bethesda, MD USA

[4] Cedar Rapids Oncol Project, Cedar Rapids, IA USA

[5] Mayo Clin, Jacksonville, FL 32224 USA

来源：

NEURO-ONCOLOGY | 2007年 / 9卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：518 / 518

页数：1

共 50 条

[21] Phase I study of temsirolimus (CCI-779), carboplatin, and paclitaxel in patients (pts) with advanced solid tumors: NCIC CTG IND 179 [J].

Oza, A. M. ;

Kollmannsberger, C. ;

Hirte, H. ;

Welch, S. ;

Siu, L. ;

Mazurka, J. ;

Sederias, J. ;

Doyle, L. A. ;

Eisenhauer, E. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)

[22] GEMCITABINE COMBINED WITH THE MTOR INHIBITOR TEMSIROLIMUS(CCI-779) IN PATIENTS WITH INOPERABLE OR METASTATIC PANCREATIC CANCER (HE 3/07). A PHASE I STUDY BY THE HELLENIC COOPERATIVE ONCOLOGY GROUP [J].

Karavasilis, V. ;

Pentheroudakis, G. ;

Sgouros, J. ;

Dimoudis, S. T. ;

Varthalitis, I. ;

Samantas, E. ;

Fountzilas, G. .

ANNALS OF ONCOLOGY, 2012, 23 :239-239

[23] Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs [J].

Susan M. Chang ;

John Kuhn ;

Patrick Wen ;

Harry Greenberg ;

David Schiff ;

Charles Conrad ;

Karen Fink ;

H. Ian Robins ;

Timothy Cloughesy ;

Lisa De Angelis ;

Jeffrey Razier ;

Kenneth Hess ;

Janet Dancey ;

Michael D. Prados .

Investigational New Drugs, 2004, 22 :427-435

[24] Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs [J].

Chang, SM ;

Kuhn, J ;

Wen, P ;

Greenberg, H ;

Schiff, D ;

Conrad, C ;

Fink, K ;

Robins, HI ;

Cloughesy, T ;

De Angelis, L ;

Razier, J ;

Hess, K ;

Dancey, J ;

Prados, MD .

INVESTIGATIONAL NEW DRUGS, 2004, 22 (04) :427-435

[25] Phase I pharmacokinetic study of temsirolimus (CCI-779) in patients with advanced malignancies and normal and impaired liver function: An NCI Organ Dysfunction Working Group (ODWG) study. [J].

Sarantopoulos, J. ;

Lenz, H. ;

LoRusso, P. ;

Shibata, S. ;

Kummar, S. ;

Mulkerin, D. ;

Ramanathan, R. K. ;

Mita, M. M. ;

O'Rourke, P. ;

Remick, S. C. ;

Goel, S. ;

Gutierrez, M. ;

Ramalingam, S. S. ;

Murgo, A. ;

Davies, A. M. ;

Mani, S. ;

Boni, J. ;

Shapiro, M. ;

Ivy, S. P. ;

Takimoto, C. H. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)

[26] Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer [J].

Chan, S ;

Scheulen, ME ;

Johnston, S ;

Mross, K ;

Cardoso, F ;

Dittrich, C ;

Eiermann, W ;

Hess, D ;

Morant, R ;

Semiglazov, V ;

Borner, M ;

Salzberg, M ;

Ostapenko, V ;

Illiger, HJ ;

Behringer, D ;

Bardy-Bouxin, N ;

Boni, J ;

Kong, S ;

Cincotta, M ;

Moore, L .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (23) :5314-5322

[27] A phase II study of temsirolimus (CCI-779) in patients with metastatic and/or locally advanced recurrent endometrial cancer previously treated with chemotherapy: NCIC CTG IND 160b [J].

Oza, A. M. ;

Elit, L. ;

Provencher, D. ;

Biagi, J. J. ;

Panasci, L. ;

Sederias, J. ;

Dancey, J. E. ;

Tsao, S. ;

Eisenhauer, E. A. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)

[28] Anti-tumor activity of single-agent CCI-779 for relapsed mantle cell lymphoma: A phase II trial in the north central cancer treatment group. [J].

Witzig, T ;

Geyer, S ;

Ghobrial, I ;

Inwards, D ;

Fonseca, R ;

Kaufmann, S ;

Kurtin, P ;

Colgan, J ;

Morice, W ;

Alberts, S ;

Salim, M ;

Rowland, K ;

Dakhil, S ;

Morton, R ;

Stella, P .

BLOOD, 2004, 104 (11) :40A-40A

[29] Effect of combined therapy with temsirolimus (CCI-779), temozolomide (TMZ), and radiation (RT) in newly diagnosed glioblastoma multiforme (GBM) patients on immune suppression: Results from NCCTG N027D [J].

Sarkaria, J. N. ;

Galanis, E. ;

Gustafson, M. P. ;

Dietz, A. B. ;

Wu, W. ;

Brown, P. D. ;

Uhm, J. H. ;

Giannini, C. ;

Jaeckle, K. A. ;

Buckner, J. C. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)

[30] Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study [J].

Galanis, Evanthia ;

Jaeckle, Kurt A. ;

Maurer, Matthew J. ;

Reid, Joel M. ;

Ames, Matthew M. ;

Hardwick, James S. ;

Reilly, John F. ;

Loboda, Andrey ;

Nebozhyn, Michael ;

Fantin, Valeria R. ;

Richon, Victoria M. ;

Scheithauer, Bernd ;

Giannini, Caterina ;

Flynn, Patrick J. ;

Moore, Dennis F., Jr. ;

Zwiebel, James ;

Buckner, Jan C. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (12) :2052-2058

← 1 2 3 4 5 →